Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 8 | 2024 | 39 | 1.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2025 | 161 | 0.740 |
Why?
|
| Vulvar Neoplasms | 2 | 2014 | 6 | 0.540 |
Why?
|
| Ovarian Neoplasms | 8 | 2025 | 85 | 0.530 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2005 | 89 | 0.470 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2024 | 159 | 0.470 |
Why?
|
| Cisplatin | 4 | 2024 | 78 | 0.420 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2011 | 168 | 0.300 |
Why?
|
| Paclitaxel | 2 | 2025 | 56 | 0.270 |
Why?
|
| Carcinoma, Endometrioid | 4 | 2019 | 14 | 0.240 |
Why?
|
| Female | 26 | 2025 | 20392 | 0.240 |
Why?
|
| Sirolimus | 2 | 2016 | 59 | 0.230 |
Why?
|
| Chemoradiotherapy | 1 | 2024 | 39 | 0.220 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2002 | 48 | 0.190 |
Why?
|
| Hysterectomy | 2 | 2017 | 38 | 0.190 |
Why?
|
| Kidney Neoplasms | 1 | 2002 | 73 | 0.190 |
Why?
|
| Humans | 26 | 2025 | 40217 | 0.160 |
Why?
|
| Middle Aged | 12 | 2025 | 10090 | 0.160 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2019 | 9 | 0.160 |
Why?
|
| Genital Neoplasms, Female | 1 | 1999 | 7 | 0.160 |
Why?
|
| Megestrol Acetate | 2 | 2016 | 2 | 0.150 |
Why?
|
| Tamoxifen | 2 | 2016 | 35 | 0.150 |
Why?
|
| Aged | 10 | 2025 | 8182 | 0.150 |
Why?
|
| Receptor, Notch2 | 1 | 2017 | 5 | 0.140 |
Why?
|
| Cervix Uteri | 1 | 1997 | 41 | 0.130 |
Why?
|
| Adult | 12 | 2025 | 10255 | 0.130 |
Why?
|
| Gynecologic Surgical Procedures | 2 | 2014 | 24 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2025 | 120 | 0.130 |
Why?
|
| Preoperative Care | 2 | 2014 | 106 | 0.120 |
Why?
|
| Mass Screening | 1 | 1999 | 409 | 0.120 |
Why?
|
| Laparoscopy | 1 | 2017 | 240 | 0.120 |
Why?
|
| Papillomaviridae | 1 | 2014 | 38 | 0.110 |
Why?
|
| Uterine Prolapse | 1 | 2014 | 13 | 0.110 |
Why?
|
| Colposcopy | 1 | 2014 | 12 | 0.110 |
Why?
|
| Endometrium | 1 | 2014 | 15 | 0.110 |
Why?
|
| Anaphylaxis | 1 | 1994 | 19 | 0.110 |
Why?
|
| Risk Factors | 3 | 2014 | 3141 | 0.110 |
Why?
|
| Papillomavirus Infections | 1 | 2014 | 80 | 0.100 |
Why?
|
| Adnexal Diseases | 1 | 1993 | 4 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2002 | 663 | 0.100 |
Why?
|
| Postoperative Care | 1 | 2013 | 67 | 0.100 |
Why?
|
| Surgical Procedures, Operative | 1 | 2013 | 75 | 0.100 |
Why?
|
| Recovery of Function | 1 | 2013 | 134 | 0.100 |
Why?
|
| MicroRNAs | 1 | 2017 | 535 | 0.090 |
Why?
|
| Herpes Zoster | 1 | 2011 | 15 | 0.090 |
Why?
|
| Lymphogranuloma Venereum | 1 | 1991 | 2 | 0.090 |
Why?
|
| Aged, 80 and over | 6 | 2017 | 3136 | 0.090 |
Why?
|
| Postoperative Complications | 3 | 2017 | 605 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2025 | 168 | 0.080 |
Why?
|
| Epothilones | 1 | 2009 | 1 | 0.080 |
Why?
|
| Tubulin Modulators | 1 | 2009 | 6 | 0.080 |
Why?
|
| Peritoneal Neoplasms | 1 | 2009 | 18 | 0.080 |
Why?
|
| Mutation | 1 | 2016 | 2123 | 0.070 |
Why?
|
| Aging | 1 | 2013 | 581 | 0.070 |
Why?
|
| Skin Neoplasms | 1 | 2011 | 281 | 0.070 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 257 | 0.070 |
Why?
|
| Deoxycytidine | 1 | 2005 | 20 | 0.060 |
Why?
|
| Hemangiosarcoma | 1 | 2005 | 20 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2024 | 1958 | 0.060 |
Why?
|
| Biopsy | 2 | 2014 | 228 | 0.060 |
Why?
|
| Brachytherapy | 1 | 2024 | 5 | 0.050 |
Why?
|
| Precancerous Conditions | 1 | 2004 | 41 | 0.050 |
Why?
|
| Diagnosis, Differential | 3 | 2011 | 520 | 0.050 |
Why?
|
| Neuralgia | 1 | 2003 | 13 | 0.050 |
Why?
|
| Lymph Node Excision | 1 | 2002 | 21 | 0.050 |
Why?
|
| Nephrectomy | 1 | 2002 | 34 | 0.050 |
Why?
|
| Retrospective Studies | 4 | 2017 | 3138 | 0.050 |
Why?
|
| Prognosis | 2 | 2002 | 921 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2024 | 326 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2014 | 663 | 0.040 |
Why?
|
| Carboplatin | 1 | 2020 | 14 | 0.040 |
Why?
|
| Filgrastim | 1 | 2020 | 5 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 40 | 0.040 |
Why?
|
| Struma Ovarii | 1 | 1999 | 1 | 0.040 |
Why?
|
| Thyrotoxicosis | 1 | 1999 | 5 | 0.040 |
Why?
|
| Age Factors | 2 | 2017 | 1069 | 0.040 |
Why?
|
| Genetic Testing | 1 | 1999 | 88 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 470 | 0.040 |
Why?
|
| Ileus | 1 | 2017 | 4 | 0.040 |
Why?
|
| Laparotomy | 1 | 2017 | 22 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 1999 | 203 | 0.030 |
Why?
|
| Intraoperative Complications | 1 | 2017 | 33 | 0.030 |
Why?
|
| Uterine Cervical Diseases | 1 | 1997 | 2 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2020 | 2863 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 154 | 0.030 |
Why?
|
| Vaginal Smears | 1 | 1997 | 34 | 0.030 |
Why?
|
| Papanicolaou Test | 1 | 1997 | 27 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2017 | 77 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 65 | 0.030 |
Why?
|
| Pneumonia | 1 | 2017 | 95 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 8 | 0.030 |
Why?
|
| Quality of Life | 1 | 2020 | 649 | 0.030 |
Why?
|
| Postmenopause | 1 | 1997 | 213 | 0.030 |
Why?
|
| Length of Stay | 1 | 2017 | 366 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2016 | 64 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 140 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 370 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 156 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 1994 | 69 | 0.030 |
Why?
|
| Ovarian Diseases | 2 | 2004 | 9 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 140 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 1997 | 1367 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 137 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 167 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 124 | 0.030 |
Why?
|
| Torsion Abnormality | 1 | 1993 | 5 | 0.030 |
Why?
|
| Fallopian Tubes | 1 | 1993 | 9 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 463 | 0.030 |
Why?
|
| Ovariectomy | 1 | 1993 | 84 | 0.030 |
Why?
|
| Cohort Studies | 1 | 1997 | 1479 | 0.030 |
Why?
|
| Morbidity | 1 | 1993 | 67 | 0.030 |
Why?
|
| Patient Positioning | 1 | 2013 | 11 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2014 | 251 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2014 | 107 | 0.030 |
Why?
|
| Ovary | 1 | 1993 | 79 | 0.030 |
Why?
|
| Adolescent | 3 | 2004 | 4034 | 0.030 |
Why?
|
| Carcinoma | 1 | 1993 | 94 | 0.020 |
Why?
|
| Delirium | 1 | 2013 | 27 | 0.020 |
Why?
|
| Forecasting | 1 | 1993 | 165 | 0.020 |
Why?
|
| Pain, Postoperative | 1 | 2013 | 66 | 0.020 |
Why?
|
| Trophoblastic Neoplasms | 1 | 1992 | 1 | 0.020 |
Why?
|
| Uterine Neoplasms | 1 | 1992 | 14 | 0.020 |
Why?
|
| Wound Healing | 1 | 2013 | 113 | 0.020 |
Why?
|
| Venous Thromboembolism | 1 | 2013 | 103 | 0.020 |
Why?
|
| Pain Management | 1 | 2013 | 87 | 0.020 |
Why?
|
| Herpesvirus 3, Human | 1 | 2011 | 9 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 34 | 0.020 |
Why?
|
| Abdominal Wall | 1 | 2011 | 12 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2011 | 29 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2011 | 90 | 0.020 |
Why?
|
| Pelvis | 1 | 1991 | 36 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2013 | 308 | 0.020 |
Why?
|
| Physical Examination | 1 | 1991 | 72 | 0.020 |
Why?
|
| Pregnancy | 2 | 1993 | 1664 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 1991 | 160 | 0.020 |
Why?
|
| Taxoids | 1 | 2009 | 8 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2009 | 12 | 0.020 |
Why?
|
| Bridged-Ring Compounds | 1 | 2009 | 7 | 0.020 |
Why?
|
| Pregnancy Complications | 1 | 1993 | 284 | 0.020 |
Why?
|
| Child | 1 | 1993 | 2856 | 0.020 |
Why?
|
| Ifosfamide | 1 | 2005 | 2 | 0.020 |
Why?
|
| Mesna | 1 | 2005 | 2 | 0.020 |
Why?
|
| Dacarbazine | 1 | 2005 | 12 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2005 | 54 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2005 | 62 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 102 | 0.010 |
Why?
|
| Amitriptyline | 1 | 2003 | 4 | 0.010 |
Why?
|
| Fallopian Tube Diseases | 1 | 2003 | 4 | 0.010 |
Why?
|
| Endometriosis | 1 | 2003 | 16 | 0.010 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2003 | 22 | 0.010 |
Why?
|
| Abscess | 1 | 2003 | 58 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2004 | 664 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2004 | 832 | 0.010 |
Why?
|
| Thyroglobulin | 1 | 1999 | 6 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2004 | 1165 | 0.010 |
Why?
|
| Triiodothyronine | 1 | 1999 | 25 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1999 | 99 | 0.010 |
Why?
|
| Cystadenoma | 1 | 1993 | 3 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1993 | 8 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 1993 | 32 | 0.010 |
Why?
|
| Dactinomycin | 1 | 1992 | 9 | 0.010 |
Why?
|
| Alleles | 1 | 1993 | 352 | 0.010 |
Why?
|
| World Health Organization | 1 | 1992 | 23 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1992 | 49 | 0.010 |
Why?
|
| Methotrexate | 1 | 1992 | 63 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1992 | 90 | 0.010 |
Why?
|
| Base Sequence | 1 | 1993 | 1114 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1993 | 1766 | 0.010 |
Why?
|
| United States | 1 | 1992 | 4886 | 0.000 |
Why?
|